Business · 1 sources covering this

Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains Underperform

Ilumya's US sales challenges, higher R&D spending, and the growth prospects of Leqselvi and Unloxcyt remain key factors shaping brokerage views on Sun Pharma.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·2h ago
Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains Underperform
Ilumya's US sales challenges, higher R&D spending, and the growth prospects of Leqselvi and Unloxcyt remain key factors shaping brokerage views on Sun Pharma.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/b3e7defbf5f51cd2ba97b7e6079b12e1201e484b"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains Underperform"></iframe>

Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains Underperform

How 1 sources are covering this

Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains Underperform

More from Business

Three rebel AAP MLAs from Punjab join BJP ahead of Assembly polls

Xiaomi Mijia Smart Air Purifier 6 review: What works & what gives me pause

Indraprastha Gas tanks 10%, hits 52-week low on disappointing Q2 results

India to export complete Vande Bharat trains in 3-4 years, says Vaishnaw

Reader

Trust & legal

Across the network